GENTAMICIN SULFATE

Manufacturer
A-S Medication Solutions
Effective date
2023-02-04
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
8
Source
legacy-cache
Hydrated at
2026-08-01 21:37:21

Label at a glance#

ProductGENTAMICIN SULFATE
Active ingredientGENTAMICIN SULFATE
Label structure10 sections

Indications and uses

Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus...

Dosage and administration

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, topical anti-infective agent for ophthalmic use.

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:

The structural formula for Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three compone...The structural formula for Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three compone...

Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide may be added to adjust pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Microbiology

Gentamicin sulfate is active in vitro against many strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Gentamicin sulfate ophthalmic solution, USP is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

Gentamicin sulfate ophthalmic solution, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible microorganisms, including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy 

PREGNANCY SECTION

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product: 50090-2333

NDC: 50090-2333-0 5 mL in a BOTTLE, DROPPER / 1 in a CARTON

gentamicin sulfate

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-2333-0ML - Milliliter50090-23331977a3ae-7ae3-4ab9-a4e0-69632008534612021-06-02
60758-188-05ML - Milliliter60758-188d155d9ac-d56c-4938-a7d3-39ee324dd1f512012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-233350090-2333-0
60758-188

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062452-001GENOPTICGENTAMICIN SULFATEEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1084e616aacf4f…
2026-08-18 06:07:402026-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A062452-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062452-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062452-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062452-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062452-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
31eb0185-a107-4d93-b6ec-ec57b9d2a38a3af46956-ecef-48d1-9f2c-9b1c0e5f18582024-09-25Warnings, Adverse reactionsExact identifier
spl set id: 3af46956-ecef-48d1-9f2c-9b1c0e5f1858

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.